" class="no-js "lang="en-US"> Karl Karlsson - Medtech Alert
Sunday, June 08, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Karl Karlsson

Karl Karlsson

About Karl Karlsson

3Z´s CEO Karl Karlsson is a PhD in behavioral neuroscience and professor in Biomedical Engineering at Reykjavik University. Karl was extensively involved in sleep research before merging the neuroscientific and engineering skillsets to high-throughput in vivo drug screening.

Related Story

Drug Development

 3Z Closes $2 Million Funding for Preclinical Development of Novel ADHD and Insomnia Therapeutics Identified by 3Z´s Zebrafish Drug Discovery Platform | Pharmtech Focus

3Z Closes $2 Million Funding for Preclinical Development of Novel ADHD and Insomnia Therapeutics Identified by 3Z´s Zebrafish Drug Discovery Platform

June 21 2022

3Z, a Reykjavik based drug discovery company is pleased to announce the closure of a $2 million funding round […]